N. Azuma, M. Takahara, A. Kodama, Y. Soga, H. Terashi, J. Tazaki, T. Yamaoka, A. Koya, O. Iida
{"title":"Predictive Model for Mortality Risk Including the Wound, Ischemia, Foot Infection Classification in Patients Undergoing Revascularization for Critical Limb Ischemia.","authors":"N. Azuma, M. Takahara, A. Kodama, Y. Soga, H. Terashi, J. Tazaki, T. Yamaoka, A. Koya, O. Iida","doi":"10.1161/CIRCINTERVENTIONS.119.008015","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008015","url":null,"abstract":"BACKGROUND\u0000The aim of this study was to develop a predictive model for mortality risk based on preoperative risk factors, including the Wound, Ischemia, Foot Infection (WIfI) classification, in patients undergoing revascularization for critical limb ischemia.\u0000\u0000\u0000METHODS\u0000We analyzed a database of the Surgical reconstruction versus Peripheral Intervention in Patients With Critical Limb Ischemia registry, a multicenter, prospective, observational study that included 520 critical limb ischemia patients (192 surgical and 328 endovascular patients).\u0000\u0000\u0000RESULTS\u0000Multivariate Cox regression analysis identified old age, impaired mobility, low body mass index, renal failure, heart failure, and high WIfI grade as independent risk factors for all-cause mortality (all P<0.05). The risk score comprising these risk factors discriminated the mortality risk well; the 2-year survival rate was >90% in the first quantile of the risk score and ≈20% in the fifth quantile. The area under the time-dependent receiver operating characteristics curve was 0.829 for thirty-day mortality and 0.811 for 2-year mortality. Adding more detailed preoperative information to the predictive model revealed that cystatin C-based estimated glomerular filtration rate, left ventricular ejection fraction, and cholinesterase levels were additional independent risk factors, but the predictive accuracy of the model was not significantly improved, according to the time-dependent receiver operating characteristics curve and net reclassification improvement.\u0000\u0000\u0000CONCLUSIONS\u0000The current study developed a risk score for mortality using preoperative risk factors, including the WIfI classification, in critical limb ischemia patients undergoing revascularization.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114641685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Dharma, N. Y. Sari, A. Parlautan, R. Sukmawan, S. Wijaya, E. Ekawati, A. Santoso
{"title":"The 3q25 rs2305619 Polymorphism Is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-Segment-Elevation Myocardial Infarction.","authors":"S. Dharma, N. Y. Sari, A. Parlautan, R. Sukmawan, S. Wijaya, E. Ekawati, A. Santoso","doi":"10.1161/CIRCINTERVENTIONS.119.008228","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008228","url":null,"abstract":"","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"16 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113941812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Reed, Angelyn O. Fairchild, F. Johnson, J. González, R. Mentz, M. Krucoff, S. Vemulapalli
{"title":"Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms.","authors":"S. Reed, Angelyn O. Fairchild, F. Johnson, J. González, R. Mentz, M. Krucoff, S. Vemulapalli","doi":"10.1161/CIRCINTERVENTIONS.119.008051","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008051","url":null,"abstract":"BACKGROUND\u0000The Food and Drug Administration's Center for Drugs and Radiological Health issued Guidance in 2016 on generating patient preference information to aid evaluation of medical devices. Consistent with this guidance, we aimed to provide quantitative patient preference evidence on benefit-risk tradeoffs relevant to transcatheter mitral valve repair versus medical therapy for patients with heart failure and symptomatic secondary mitral regurgitation.\u0000\u0000\u0000METHODS\u0000A discrete-choice experiment survey was designed to quantify patients' tolerance for 30-day mortality or serious bleeding risks to achieve improvements in physical functioning or reductions in heart failure hospitalizations. Two samples were recruited: an online US panel of individuals reporting a diagnosis of heart failure (n=244) and patients with heart failure treated at Duke University Health System (n=175). Random-effects logit regression was used to model treatment choices as a function of benefit and risk levels.\u0000\u0000\u0000RESULTS\u0000Across both samples, approximately one-quarter (23.5%) consistently chose device profiles offering the higher level of physical functioning despite mortality and bleeding risks as high as 10%. Among respondents who at least once chose a device profile offering a lower level of functioning, improvement in physical functioning equivalent to a change from New York Heart Association class IV to III was ≈6 times more preferred than a change from New York Heart Association class III to II. Estimated discrete-choice experiment utility gains and losses revealed that respondents would accept up to a 9.7 percentage-point (95% CI, 8.2%-13.3%) increase in risk of 30-day mortality with devices that could improve functioning from New York Heart Association class IV to III, or up to 2.0% (95% CI, 1.4%-2.7%) for an improvement from New York Heart Association class III to II.\u0000\u0000\u0000CONCLUSIONS\u0000Severity of heart failure symptoms influences patients' willingness to accept risks associated with mitral valve medical devices. These findings can inform shared decision-making discussions with patients who are being evaluated for transcatheter mitral valve repair.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128472283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Megaly, C. Khalil, M. Saad, Iosif Xenogiannis, Mohamed A. Omer, Mahesh Anantha Narayanan, A. Pershad, S. Garcia, A. Seto, M. N. Burke, E. Brilakis
{"title":"Outcomes With Deferred Versus Performed Revascularization of Coronary Lesions With Gray-Zone Fractional Flow Reserve Values.","authors":"M. Megaly, C. Khalil, M. Saad, Iosif Xenogiannis, Mohamed A. Omer, Mahesh Anantha Narayanan, A. Pershad, S. Garcia, A. Seto, M. N. Burke, E. Brilakis","doi":"10.1161/CIRCINTERVENTIONS.119.008315","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008315","url":null,"abstract":"BACKGROUND\u0000Management of coronary lesions with fractional flow reserve values in the gray zone (0.75-0.80) remains controversial due to conflicting data on the performance versus deferral of revascularization.\u0000\u0000\u0000METHODS\u0000We performed a systematic review and meta-analysis of 7 observational studies including 2683 patients that compared the outcomes of deferred versus performed revascularization of coronary lesions with gray-zone fractional flow reserve values.\u0000\u0000\u0000RESULTS\u0000During a mean follow-up of 31±9 months, the incidence of major adverse cardiovascular events (12.54 % versus 11.25%; odds ratio [OR], 1.64 [95% CI, 0.78-3.44]; P=0.19, I2=84%), cardiac mortality (1.25% versus 0.72%; OR, 1.78 [95% CI, 0.58-5.46]; P=0.31, I2=18%), and myocardial infarction (1.28% versus 2.66%; OR, 0.79 [95% CI, 0.22-2.79]; P=0.71, I2=65%) was similar with deferral versus performance of revascularization in coronary lesions with gray-zone fractional flow reserve. Deferral of revascularization was associated with a higher incidence of target vessel revascularization (9.12% versus 5.78%; OR, 1.85 [95% CI, 1.03-3.33]; P=0.04, I2=62%). When the analysis was limited only to studies that used percutaneous coronary intervention for revascularization, deferred revascularization remained associated with a higher risk of target vessel revascularization (18% versus 7.3%; OR, 3.04 [95% CI, 1.53-6.02]; P<0.001) and was associated with a higher risk of major adverse cardiovascular event (23.2% versus 13.4%; OR, 3.38 [95% CI, 1.92-5.95]; P<0.001).\u0000\u0000\u0000CONCLUSIONS\u0000In lesions with gray-zone fractional flow reserve, revascularization was associated with a similar incidence of major adverse cardiovascular event but a lower incidence of target vessel revascularization over a mean follow-up of approximately 2.5 years.\u0000\u0000\u0000CLINICAL TRIAL REGISTRATION\u0000URL: https://www.crd.york.ac.uk/prospero/. Unique identifier: CRD42019128076.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117135029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anish Badjatiya, P. Merrill, J. Buse, S. Goodman, S. Goodman, B. Katona, N. Iqbal, N. Pagidipati, N. Sattar, R. Holman, Adrian F. Hernandez, R. Mentz, M. Patel, W. S. Jones
{"title":"Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.","authors":"Anish Badjatiya, P. Merrill, J. Buse, S. Goodman, S. Goodman, B. Katona, N. Iqbal, N. Pagidipati, N. Sattar, R. Holman, Adrian F. Hernandez, R. Mentz, M. Patel, W. S. Jones","doi":"10.1161/CIRCINTERVENTIONS.119.008018","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008018","url":null,"abstract":"BACKGROUND\u0000Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater incidence of diabetes mellitus and risk for LEA, prompting this investigation of clinical outcomes in patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering).\u0000\u0000\u0000METHODS\u0000EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo on the rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke) among patients with type 2 diabetes mellitus. In this post hoc analysis, we assessed the association of baseline PAD with rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PAD.\u0000\u0000\u0000RESULTS\u0000EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00-1.27]; P=0.047). Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P<0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P<0.001). Patients treated with exenatide or placebo had similar rates of MACE and LEA, regardless of PAD status.\u0000\u0000\u0000CONCLUSIONS\u0000EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without PAD. There were no differences in MACE or LEA rates with exenatide versus placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"142 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131400321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmed Elkaryoni, A. Chhatriwalla, K. Kennedy, J. Saxon, D. Cohen, S. Arnold
{"title":"Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair: A Nationwide Cohort Sample.","authors":"Ahmed Elkaryoni, A. Chhatriwalla, K. Kennedy, J. Saxon, D. Cohen, S. Arnold","doi":"10.1161/CIRCINTERVENTIONS.119.008342","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008342","url":null,"abstract":"","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131271255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Aksoy, C. Salazar, M. Becher, V. Tiyerili, Marcel Weber, F. Jansen, A. Sedaghat, S. Zimmer, J. Leick, E. Grube, N. Gonzalo, J. Sinning, J. Escaned, G. Nickenig, N. Werner
{"title":"Intravascular Lithotripsy in Calcified Coronary Lesions: A Prospective, Observational, Multicenter Registry.","authors":"A. Aksoy, C. Salazar, M. Becher, V. Tiyerili, Marcel Weber, F. Jansen, A. Sedaghat, S. Zimmer, J. Leick, E. Grube, N. Gonzalo, J. Sinning, J. Escaned, G. Nickenig, N. Werner","doi":"10.1161/CIRCINTERVENTIONS.119.008154","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008154","url":null,"abstract":"BACKGROUND\u0000Optimal plaque preparation of calcified coronary lesions is key to prevent stent failure. The purpose of this study was to determine the strategy success and safety of intravascular lithotripsy (IVL) in calcified lesions of an all-comers cohort.\u0000\u0000\u0000METHODS\u0000Patients with calcified coronary lesions were screened in 3 centers. Seventy-one patients were eligible for IVL. Patients were assigned to (group A) primary IVL therapy for patients with calcified de-novo lesions (n=39 lesions), (group B) secondary IVL therapy for patients with calcified lesions in which noncompliant balloon dilatation failed (n=22 lesions), and (group C) tertiary IVL therapy in patients with stent underexpansion after previous stenting (n=17 lesions). Primary end point was strategy success (stent expansion with <20% in-stent residual stenosis) and safety outcomes (procedural complications, in-hospital major adverse cardiovascular event).\u0000\u0000\u0000RESULTS\u0000Seventy-eight calcified lesions were treated using the Shockwave C2 balloon. Mean diameter stenosis of calcified lesions was 71.8±13.1% at baseline, decreased to 45.1±17.4% immediately after IVL, and to 17.5±15.2% after stenting. Mean minimal lumen diameter was 1.01±0.49 mm at baseline and increased to 1.90±0.61 after IVL, and to 2.88±0.56 mm after stenting. The primary end point of strategy success was reached in 84.6% (group A), 77.3% (group B), and 64.7% (group C). Device delivery and IVL treatment were possible in all lesions. Four type b dissections were observed without further sequelae. No patient suffered from in-hospital major adverse cardiovascular event. Seven Shockwave balloons ruptured during treatment without any sequelae.\u0000\u0000\u0000CONCLUSIONS\u0000IVL provides a valid strategy for lesion preparation in severely calcified coronary lesions with high success rate, low procedural complications, and low major adverse cardiovascular event rates.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126115334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rajesh Gupta, A. Kirtane, Yangbo Liu, Aaron Crowley, B. Witzenbichler, M. Rinaldi, D. Metzger, G. Weisz, T. Stuckey, B. Brodie, R. Mehran, O. Ben-Yehuda, G. Stone
{"title":"Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.","authors":"Rajesh Gupta, A. Kirtane, Yangbo Liu, Aaron Crowley, B. Witzenbichler, M. Rinaldi, D. Metzger, G. Weisz, T. Stuckey, B. Brodie, R. Mehran, O. Ben-Yehuda, G. Stone","doi":"10.1161/CIRCINTERVENTIONS.119.007982","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.007982","url":null,"abstract":"BACKGROUND\u0000Smoking is a potent risk factor for coronary artery disease; however, prior studies describe increased platelet inhibition with clopidogrel among smokers, and some studies report improved outcomes among smokers, a finding described as the smoker's paradox. This study assessed the relationship between platelet reactivity and clinical outcomes after percutaneous coronary interventions among current smokers and nonsmokers.\u0000\u0000\u0000METHODS\u0000ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a prospective, multicenter registry of patients treated with coronary drug-eluting stents. Platelet reactivity was assessed by the VerifyNow point-of-care assay; high on-treatment platelet reactivity (HPR) was defined as P2Y12 reaction units >208. A propensity-adjusted multivariable analysis was performed to determine the relationship between current smoking, platelet reactivity, and subsequent adverse events.\u0000\u0000\u0000RESULTS\u0000Among 8582 patients, 22.6% were active smokers at the time of their percutaneous coronary intervention procedure. Current smokers were younger and had fewer comorbidities compared with nonsmokers. Current smokers had lower mean P2Y12 reaction units and lower rates of HPR compared with nonsmokers. Current smokers had similar rates of adverse events compared with nonsmokers. HPR was associated with higher rates of adverse events for both smokers and nonsmokers; however, there was evidence of interaction between smoking status and the effect of HPR. Smokers with HPR had significantly higher rates of stent thrombosis. Adverse event rates were highest among current smokers with HPR.\u0000\u0000\u0000CONCLUSIONS\u0000Current smoking was associated with lower P2Y12 reaction units and lower rates of HPR on average; however, the combination of current smoking and HPR was associated with high rates of stent thrombosis.\u0000\u0000\u0000CLINICAL TRIAL REGISTRATION\u0000URL: https://www.clinicaltrials.gov. Unique identifier: NCT00638794.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"151 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122429147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Infective Endocarditis Following Transcatheter Aortic Valve Replacement: Comparison of Balloon- Versus Self-Expandable Valves.","authors":"A. Regueiro","doi":"10.1161/CIRCINTERVENTIONS.119.007938","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.007938","url":null,"abstract":"BACKGROUND\u0000No data exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic valve replacement (TAVR) according to transcatheter valve type. We aimed to determine the incidence, clinical characteristics, and outcomes of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding valve (SEV) systems.\u0000\u0000\u0000METHODS\u0000Data from the multicenter Infectious Endocarditis After TAVR International Registry was used to compare IE patients with BEV versus SEV.\u0000\u0000\u0000RESULTS\u0000A total of 245 patients with IE post-TAVR were included (SEV, 47%; BEV, 53%). The timing between TAVR and IE was similar between groups (SEV, 5.5 [1.2-15] months versus BEV, 5.3 [1.7-11.4] months; P=0.89). Enterococcal IE was more frequent in the SEV group (36.5% versus 15.4%; P<0.01), and vegetation location differed according to valve type (stent frame, SEV, 18.6%; BEV, 6.9%; P=0.01; valve leaflet, SEV, 23.9%; BEV, 38.5%; P=0.01). BEV recipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46, 95% CI: 1.04-5.82, P=0.04). Surgical explant of the transcatheter valve (SEV, 8.7%; BEV, 13.8%; P=0.21), and in-hospital death at the time of IE episode (SEV, 35.6%; BEV, 37.7%; P=0.74) were similar between groups. After a mean follow-up of 13±12 months, 59.1% and 54.6% of the SEV and BEV recipients, respectively, had died (P=0.66).\u0000\u0000\u0000CONCLUSIONS\u0000The characteristics of IE post-TAVR, including microorganism type, vegetation location, and embolic complications but not early or late mortality, differed according to valve type. These results may help to guide the diagnosis and management of IE and inform future research studies in the field.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"26 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132941805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Strom, Yuansong Zhao, K. Faridi, Hector Tamez, Neel M. Butala, Linda R. Valsdottir, J. Curtis, J. M. Brennan, Changyu Shen, Mike Boulware, J. Popma, R. Yeh
{"title":"Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study.","authors":"J. Strom, Yuansong Zhao, K. Faridi, Hector Tamez, Neel M. Butala, Linda R. Valsdottir, J. Curtis, J. M. Brennan, Changyu Shen, Mike Boulware, J. Popma, R. Yeh","doi":"10.1161/CIRCINTERVENTIONS.119.008231","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.119.008231","url":null,"abstract":"BACKGROUND\u0000Cerebrovascular events (CVEs) are devastating complications after aortic valve replacement. We assessed whether billing claims accurately identify CVEs in place of clinical event adjudication in structural heart disease trials.\u0000\u0000\u0000METHODS\u0000Adult participants in the US CoreValve High Risk and SURTAVI trials (Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients) were linked to Medicare inpatient claims from January 1, 2006 to December 31, 2016. Claims consistent with CVEs within 14 days of a similar trial-adjudicated CVE were considered a match. The sensitivity, specificity, and positive and negative predictive values of International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification billing codes for cerebrovascular disease were determined against trial-defined CVEs as the criterion standard. Kaplan-Meier estimates of claims-defined versus trial-defined CVEs were compared.\u0000\u0000\u0000RESULTS\u0000Among 4230 linked trial participants (linkage rate 79.8%), 550 (13.0%) sustained 630 adjudicated CVEs over a 5-year follow-up period. Linked and nonlinked individuals were similar. An algorithm using 4 International Classification of Diseases, Ninth Revision, Clinical Modification codes (434.91, 434.11, 433.11, and 997.02) had a sensitivity of 60.9%, specificity of 99.0%, positive predictive value of 86.5%, and negative predictive value of 95.8% for identifying a trial-adjudicated ischemic stroke. An algorithm using 3 International Classification of Diseases, Tenth Revision, Clinical Modification codes (I63.9, I63.40, I63.49) had a sensitivity of 66.7%, specificity of 99.4%, positive predictive value of 88.9%, and negative predictive value of 97.6%.\u0000\u0000\u0000CONCLUSIONS\u0000In linked clinical trial and Medicare claims data, 4 International Classification of Diseases, Ninth Revision, Clinical Modification and 3 International Classification of Diseases, Tenth Revision, Clinical Modification billing codes identified half of trial-adjudicated CVEs during follow-up with high specificity and predictive value, but imperfect sensitivity. Although low sensitivity may limit the use of claims to substitute for traditional trial outcomes to identify CVEs, high specificity suggests claims could be used to trigger evaluation of neurological events, potentially improving the efficiency of the evaluation of techniques and devices designed to reduce such events.","PeriodicalId":383310,"journal":{"name":"Circulation: Cadiovascular Interventions","volume":"4 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120873698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}